A feasibility and safety study of afamelanotide in acute stroke patients – an open label, proof of concept, phase iia clinical trial [PDF]
BMC Neurology, 2023 Background Neuroprotective agents have the potential to improve the outcomes of revascularisation therapies in acute ischemic stroke patients (AIS) and in those unable to receive revascularisation.
Vimal Stanislaus +6 more
doaj +2 more sources
Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria [PDF]
Life, 2023 In animal models, melanocyte-stimulating hormones (MSHs) protect the liver from various injuries. Erythropoietic protoporphyria (EPP), a metabolic disorder, leads to the accumulation of protoporphyrin (PPIX).
Anna-Elisabeth Minder +4 more
doaj +2 more sources
When the diagnosis is written in the DNA: a case of erythropoietic protoporphyria in a patient with a chromosome 18 deletion [PDF]
Dermatology Reports, 2023 We present a case of erythropoietic protoporphyria (EPP) in a 21-year-old man who sought medical attention in April 2022 due to diffuse edema and erythema of the hands, which he had been experiencing since childhood and occurring shortly after sun ...
Sara Rovaris +8 more
doaj +2 more sources
Computational Screening of Approved Drugs for Inhibition of the Antibiotic Resistance Gene mecA in Methicillin-Resistant Staphylococcus aureus (MRSA) Strains [PDF]
BioTech, 2023 Antibiotic resistance is a critical problem that results in a high morbidity and mortality rate. The process of discovering new chemotherapy and antibiotics is challenging, expensive, and time-consuming, with only a few getting approved for clinical use.
Benson Otarigho, Mofolusho O. Falade
doaj +2 more sources
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria [PDF]
Expert Review of Clinical Pharmacology, 2021 Introduction: In erythropoietic protoporphyria (EPP), an inherited disorder of heme biosynthesis, accumulation of protoporphyrin IX results in acute phototoxicity. EPP patients experience severe burning pain after light exposure, which results in a markedly reduced quality of life. Afamelanotide is the first effective approved medical treatment for EPP,
Debby Wensink +2 more
openaire +2 more sources
Therapeutic Advances in Rare Disease, 2021 Erythropoietic protoporphyria (EPP) is an ultra-rare inherited disorder with overproduction of protoporphyrin in maturating erythroblasts. This excess protoporphyrin leads to incapacitating phototoxic burns in sunlight exposed skin.
Anna-Elisabeth Minder +6 more
doaj +1 more source
Characteristics of childhood vitiligo and the progress of its treatment
Pifu-xingbing zhenliaoxue zazhi, 2022 Vitiligo is a common depigmentation disease. Childhood vitiligo exhibits some characteristics in epidemiology, clinical manifestations, comorbidities, etc.
Xiuzhen LI, Xiulian XU
doaj +1 more source
Erythropoietic protoporphyria and afamelanotide: a patient’s perspective
Clinical and Experimental Dermatology, 2023 The patient explores the profound impact of erythropoietic protoporphyria (EPP) on her life to date. The clinician’s comment reviews the symptoms and diagnostic criteria for EPP, as well as the novel treatment afamelanotide for EPP.
O'Reilly, Marese +2 more
openaire +3 more sources
2019 FDA TIDES (Peptides and Oligonucleotides) Harvest
Pharmaceuticals, 2020 2019 has been an excellent year in terms of peptides and oligonucleotides (TIDES) approved by the FDA. Despite the drop in the number of total drugs approved by the FDA in 2019 in comparison with 2018 (48 vs.
Danah Al Shaer +3 more
doaj +1 more source
Orphanet Journal of Rare Diseases, 2020 Background Erythropoietic protoporphyria (EPP) is an ultra-rare genetic disorder (prevalence 1:150`000) characterized by instant painful phototoxic burn reactions in skin exposed to visible light.
Jasmin Barman-Aksözen +3 more
doaj +1 more source